To the full analysis
Core Laboratories stock: growth
CLBCore Laboratories reported $526.52M in revenue for fiscal 2025, up 0.5% on the prior year, up 1.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−0.5%
per year from 2006 to 2025, per share −0.1%
Earnings (Annual rate)
−5.3%
per year from 2006 to 2025, per share −4.6%
Free cash flow (Annual rate)
−7.4%
per year from 2006 to 2025, per share −7%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 1.6% | −4.1% | −0.5% |
| Revenue per share | 0.7% | −5.0% | −0.1% |
| Earnings | no data | −12.7% | −5.3% |
| Earnings per share | no data | −12.9% | −4.6% |
| Free cash flow | −13.5% | −19.5% | −7.4% |
| Free cash flow per share | −14.2% | −20.2% | −7.0% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $575.69M | $82.66M | $95.62M |
| 2007 | $670.54M | $121.11M | $101.55M |
| 2008 | $780.84M | $143.6M | $123.9M |
| 2009 | $695.54M | $113.6M | $164.34M |
| 2010 | $794.65M | $144.92M | $178.03M |
| 2011 | $907.65M | $184.68M | $173.98M |
| 2012 | $981.08M | $216.07M | $204.4M |
| 2013 | $1.07B | $242.81M | $259.19M |
| 2014 | $1.09B | $257.49M | $266.01M |
| 2015 | $797.52M | $114.85M | $194.84M |
| 2016 | $594.74M | $63.9M | $120.18M |
| 2017 | $659.81M | $83.13M | $105.5M |
| 2018 | $700.85M | $79.53M | $90.09M |
| 2019 | $668.21M | $101.98M | $67.26M |
| 2020 | $487.27M | −$97.64M | $45.99M |
| 2021 | $470.25M | $19.73M | $23.04M |
| 2022 | $489.74M | $19.45M | $14.74M |
| 2023 | $509.79M | $36.68M | $14.21M |
| 2024 | $523.85M | $31.4M | $43.36M |
| 2025 | $526.52M | $29.67M | $22.29M |
Revenue by segment
How Core Laboratories N.V. makes its money and how that has shifted. Names are as the company reports them.
- Service76%
- Product24%
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| Service | $371.91M | $388.21M | $399.42M | 75.9% |
| Product | $137.88M | $135.64M | $127.1M | 24.1% |
| Total revenue | $509.79M | $523.85M | $526.52M | 100% |
Revenue by region
Where Core Laboratories N.V. generates its revenue.
- Outside the US$351.2M67%
- United States$175.3M33%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Outside the US | $351.19M | 66.7% |
| United States | $175.33M | 33.3% |
| Total revenue | $526.52M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 11 Sep 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.